Vail Scientific, which empowers healthcare providers with cutting-edge solutions for early sepsis screening, has unveiled the significant new design of its proprietary VSNO™ sepsis screening device, which is used for speeding sepsis testing and results for enhanced patient outcomes.
Vail Scientific Taps Minnetronix to Redesign Device for Earlier, Faster Sepsis Screening Read Post »
Research Article: Evaluation of the Diagnostic Accuracy of Exhaled Nitric Oxide as a Marker of Infection and Sepsis in Emergency Department Patients
Clinical Trial Published in Emergency Medicine International Read Post »
Recent Press: Vail Scientific was featured in Medical Design & Outsourcing.
First Look: Vail Scientific’s redesigned VSNO device for rapid sepsis screening Read Post »
Exit 156 is proud to announce a $2.0 Million investment in Vail Scientific Inc., a pioneering company based in Minneapolis, Minnesota developing a diagnostic tool for screening patients suspected of having sepsis as an aid in triage. This investment will accelerate Vail Scientific’s development of its groundbreaking VSNOTM technology, which allows for real-time, non-invasive, and point-of-care screening of patients suspected of having sepsis.
Exit 156 Invests in Vail Scientific, Inc. Read Post »
At the end of August 2021, Vail Scientific successfully closed an oversubscribed round. The round was led by Vail Investor Group and its leader and Vail board member, Mike Nathan. Nathan shares, “I, along with the Vail Investor Group, have a real passion for transformative innovation. Sepsis diagnosis is a space that needs disruption. We are excited about the potential applications of this science.”
Vail Successfully Completes Initial Fundraise Read Post »
Our work continues because patients with sepsis cannot wait. Vail Scientific is pleased to announce the official start of its proof-of-concept NO-SEPSIS clinical study with HealthPartners. It will be conducted at HealthPartners facilities in the Minneapolis-St. Paul area. Thanks to our previous pilot study we were able to identify two statistically significant measurements. These measurements
Vail Launches NO-SEPSIS Trial Read Post »
